In the last trading session, 5.17 million shares of the AbCellera Biologics Inc (NASDAQ:ABCL) were traded, and its beta was 0.68. Most recently the company’s share price was $5.11, and it changed around $0.09 or 1.79% from the last close, which brings the market valuation of the company to $1.53B. ABCL currently trades at a discount to its 52-week high of $5.82, offering almost -13.89% off that amount. The share price’s 52-week low was $1.89, which indicates that the current value has risen by an impressive 63.01% since then. We note from AbCellera Biologics Inc’s average daily trading volume that its 10-day average is 8.07 million shares, with the 3-month average coming to 6.06 million.
AbCellera Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended ABCL as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. AbCellera Biologics Inc is expected to report earnings per share of -0.16 for the current quarter.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Instantly ABCL has showed a green trend with a performance of 1.79% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 5.82 on recent trading dayincreased the stock’s daily price by 12.2%. The company’s shares are currently up 64.84% year-to-date, but still up 14.06% over the last five days. On the other hand, AbCellera Biologics Inc (NASDAQ:ABCL) is 34.47% up in the 30-day period. We can see from the shorts that 35.72 million shares have been sold at a short interest cover period of 5.2 day(s).
The consensus price target as assigned by Wall Street analysts is $23.5, which translates to bulls needing to increase their stock price by 78.26% from its current value. Analyst projections state that ABCL is forecast to be at a low of $5 and a high of $34.
AbCellera Biologics Inc (ABCL) estimates and forecasts
The year-over-year growth rate is expected to be -7.37%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 7.7M in revenue for the current quarter. 9 analysts expect AbCellera Biologics Inc to make 7.83M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 7.32M and 6.51M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 5.11%. Forecasts for the next quarter put sales growth at 20.26%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -107.74%. AbCellera Biologics Inc earnings are expected to increase by -11.29% in 2025, but the outlook is positive 0.83% per year for the next five years.
ABCL Dividends
AbCellera Biologics Inc’s next quarterly earnings report is expected to be released on 2025-Jun-13.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 22.97% of AbCellera Biologics Inc shares, and 44.75% of them are in the hands of institutional investors. The stock currently has a share float of 58.09%. AbCellera Biologics Inc stock is held by 181.0 institutions, with BAKER BROS. ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 9.3556% of the shares, which is about 27.53 million shares worth $81.48 million.
BAILLIE GIFFORD & CO, with 7.4472% or 21.91 million shares worth $64.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
SMALLCAP WORLD FUND INC and iShares Trust-iShares Biotechnology ETF were the top two Mutual Funds as of Mar 31, 2025 . The former held 13.36 shares worth $68.28 million, making up 4.48% of all outstanding shares. On the other hand, iShares Trust-iShares Biotechnology ETF held roughly 1.33 shares worth around $6.8 million, which represents about 0.45% of the total shares outstanding.
